John Hancock medical and actual control record for audit restructuring or change-tom365.com

John Hancock medical and actual control record for audit restructuring has changed or hot column capital flows thousands of thousands of stocks the latest Rating Rating diagnosis simulation trading client Sina Level2:A shares Sina speed Kanpan finance client: the most profitable investors are using the reporter Qi Doug, editor Quan Zeyuan John Hancock medical recent youdianfan. The merger case has just been questioned by the Shenzhen Stock Exchange, and the CSRC’s "investigation notice" is placed in front of it. On the evening of 2, the company announced that in February 1st the company chairman, John Hancock medical and controlling shareholder, the actual control of Que Wenbin received the commission the "investigation notice", because the letter Phi company suspected of violating securities laws and regulations, the controlling shareholder of the company and the actual control of Que Wenbin suspected of violating securities laws and regulations, the Commission decided to Chinese company and Que Wenbin examiner. And in the 2 month 1 day, the Shenzhen stock exchange for the company recently disclosed a merger issued a letter of inquiry, questioning the restructuring case early payment of 1.1 million yuan "Chengyijin" from where, with business practices, whether the alleged or suspected disguised damages the interests of listed companies to provide financial aid etc.. As the company and the real controller fall into the case of checking and checking, whether the reorganization will be changed or not, it is worth paying close attention to. Strange "Chengyijin" specifically John Hancock medical acquisition draft, the company intends to purchase its holdings of John Hancock medical to Zhu Zhizhong 70% equity, the transaction price of 123 million 900 thousand yuan. It is reported that the second hospital of Chongzhou is a for-profit two class a general hospital with medical, teaching, research, rehabilitation, prevention and health care as one. After the completion of this transaction, the second hospital of Chongzhou will become a subsidiary of the John Hancock medical. The hospital achieved net profit of 4 million 632 thousand and 200 yuan in 1-9 months in 2015. However, this seemingly simple asset acquisition case was caused by a "sincere agreement" between the two sides of the transaction. It is understood that, in December 29, 2015, and the second hospital of Chongzhou Hengkang medical and Zhu Zhizhong signed the "Chengyijin agreement" agreement, the company intends to cash to buy 70% stake in the second hospital of Chongzhou, to meet the conditions stipulated in the agreement, the company commissioned two to Zhu Zhizhong’s accounts receivable payment equity purchase Chengyijin 110 million yuan. Among them, the first phase of 80 million yuan Chengyijin, meet the needs of both sides to establish technical service cooperation, the second hospital of Chongzhou and the subject of the company’s supply chain has been unified by the company management 5 prerequisite after payment; while second Chengyijin 30 million yuan, Zhu Zhizhong has been in the original Chongzhou second people hospital acquired community in Chongyang town of Chongzhou the city of West Bridge of state-owned land use rights to change the subject company name after payment. The two sides agreed to pay Chengyijin, John Hancock medical, the company management activities of the company have the right to supervise the subject; the second hospital of Chongzhou Zhu Zhizhong and the purchase and sale of more than 500 thousand yuan of assets shall obtain the written consent of the company; has veto power on major matters of the company and the target company Chongzhou second hospital. If the second hospital of Chongzhou and Zhu Zhizhong violated the obligations stipulated in the agreement on earnest money, 1.2 times of earnest money should be returned to the company; if the acquisition of the equity has not been approved by the board of directors, the general meeting of shareholders or the relevant departments, the second hospital of Chongzhou and Zhu Zhizhong’s Theory

恒康医疗及实控人被立案稽查重组事宜或生变 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经Level2:A股极速看盘 新浪财经客户端:最赚钱的投资者都在用   ⊙记者 祁豆豆 ○编辑 全泽源   恒康医疗最近有点烦。并购案刚被深交所问询,证监会的《调查通知书》又摆在了面前。   2日晚,公司公告称,2月1日恒康医疗及公司董事长、控股股东、实控人阙文彬分别收到证监会《调查通知书》,因公司信披涉嫌违反证券法律法规、公司控股股东及实控人阙文彬涉嫌违反证券法律法规,中国证监会决定对公司及阙文彬进行立案稽查。   而就在2月1日,深交所针对公司日前披露的一宗并购案发出问询函,质问重组案中提前支付的1.1亿元“诚意金”师出何名,是否符合商业惯例,是否涉嫌损害上市公司利益或涉嫌变相提供财务资助等。   随着公司及实控人陷入立案稽查风波,上述重组事宜是否会因此生变,值得继续关注。   奇特的“诚意金”   具体来看恒康医疗此次收购草案,公司拟向朱志忠购买其持有的恒康医疗70%股权,交易价格1.239亿元。据悉,崇州二院是一所集医、教、研、康复、预防保健为一体的营利性二级甲等综合医院。本次交易完成后,崇州二院将成为恒康医疗的控股子公司。该院2015年1-9月实现净利润463.22万元。   然而这起看似简单的资产收购案却因交易双方的一纸《诚意金协议》泛起波澜。据了解,2015年12月29日,恒康医疗与崇州二院及朱志忠签署了《诚意金协议》,该协议约定公司拟现金收购崇州二院70%的股权,在满足协议约定前提条件下,公司分两期向朱志忠的委托收款账户支付股权收购诚意金1.1亿元。   其中,第一期诚意金8000万元,需满足双方建立技术服务合作关系、崇州二院及标的公司供应链已由公司统一管理等5个前提条件后支付;而第二期诚意金3000万元,在朱志忠已将原崇州市第二人民医院购入的崇州市崇阳镇西桥社区的国有土地使用权变更至标的公司名下后支付。   双方约定,在恒康医疗支付诚意金后,公司有权监督标的公司经营管理活动;朱志忠及崇州二院购买、出售50万元以上资产应取得公司的书面同意;公司对崇州二院及标的公司重大事项具有否决权。若崇州二院及朱志忠违反《诚意金协议》约定义务,应向公司返还1.2倍诚意金;如本次股权收购事项未获得公司董事会、股东大会或相关部门核准通过,崇州二院及朱志忠应返还全部诚意金并按银行同期贷款利率支付利息,崇州二院、朱志忠对诚意金返还、逾期利息支付及违约金,承担连带责任。   监管层深度追问   对此,深交所2月1日出具问询函指出,恒康医疗提前支付1.1亿元诚意金的原因、必要性,上述做法是否符合商业惯例、是否涉嫌损害上市公司利益或涉嫌变相为其提供财务资助?同时,深交所要求公司补充披露,如本次交易未成功,则双方约定的归还诚意金并支付利息的约定的可执行性及上市公司是否已采取了保证上述款项安全的措施等,并就可能存在的款项无法收回风险做提示,请独立财务顾问就上述事项及交易对方的履约能力进行核查并发表专业意见。   此外,该笔诚意金的资金来源也受到监管部门质疑。根据恒康医疗1月22日披露的《关于变更部分募集资金用途的公告》,公司拟终止“萍乡市赣西医院有限公司整体改造项目”,并将相关募集资金变更为支付公司收购崇州二院70%股权的对价。   对此,深交所要求公司在《报告书》中补充披露收购崇州二院的资金来源,并结合原募投项目可行性研究报告、市场需求等补充披露募集资金投向发生变更的具体原因及其合理性。请独立财务顾问核实公司已支付的1.1亿元诚意金的来源及是否存在涉嫌违规使用募集资金情形并发表专业意见。   值得一提的是,收购崇州二院仅是恒康医疗本次重大资产收购的三分之一。据悉,公司拟购标的资产还包括武汉市商业职工医院及一家海外公司。公司最新重组进展显示,目前公司已完成对海外公司的全面尽职调查工作,并与交易对方就收购海外公司细节进行深入洽谈;而因商职医院涉及股东众多,资产权属较为复杂,收购方案则在进一步细化和完善中。对此,深交所也在重组问询函中表示,请补充披露停牌期间公司收购上述两家标的已完成的具体工作、后续推进计划以及预计完成时间。   “立案稽查”新忧   恒康医疗2月2日晚间公告,2月1日,公司及公司董事长、控股股东、实际控制人阙文彬分别收到证监会《调查通知书》。   因公司信息披露涉嫌违反证券法律法规、公司控股股东及实际控制人阙文彬涉嫌违反证券法律法规,根据《中华人民共和国证券法》的有关规定,证监会决定对公司及阙文彬进行立案稽查。   如公司因此受到证监会行政处罚,并在行政处罚决定书中被认定构成重大违法行为,或者因涉嫌违规披露、不披露重要信息罪被依法移送公安机关的,公司将因触及《深圳证券交易所股票上市规则(2014年修订)》13.2.1条规定的重大信息披露违法情形,公司股票交易将被实行退市风险警示。   不过值得注意的是,公司及阙文彬是被“立案稽查”,而非“立案调查”。据专业人士解释称,稽查的立案主体应是证监会稽查部门。THE_END 进入【新浪财经股吧】讨论相关的主题文章: